What is Biomemory?
Biomemory is an emerging startup focused on revolutionizing data storage through synthetic biology. The company is developing a DNA-based data storage solution designed to offer a more sustainable, durable, and compact alternative to conventional memory, disk, and tape technologies. These traditional media are often characterized by their fragility, large physical footprint, and significant environmental impact, positioning Biomemory's innovation as a critical advancement for long-term data archiving and preservation.
How much funding has Biomemory raised?
Biomemory has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2022): $5M with participation from French Tech and EureKARE
Key Investors in Biomemory
French Tech
French Tech is a government initiative dedicated to fostering the growth of French startups, supporting technological sovereignty and innovation through various programs for scale-ups and emerging companies.
EureKARE
EureKARE is a project development company operating within the biotechnology industry, focusing on advancing new ventures in the life sciences sector.
What's next for Biomemory?
With this major enterprise-level funding and strategic investment, Biomemory is poised to accelerate its research and development efforts, scale its synthetic biology processes, and potentially move towards commercialization. The substantial capital infusion suggests a strong investor confidence in the company's disruptive technology and its potential to address the growing global demand for efficient and eco-friendly data storage solutions. Future developments will likely focus on enhancing data density, read/write speeds, and the long-term stability of DNA storage, paving the way for a new era in information management.
See full Biomemory company page
